Pair page
Argireline with Syn-Coll
Mechanism-tag overlap and published literature for Argireline and Syn-Coll, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
snap-25-mimetic
cosmetic-peptide
tgf-mimetic-collagen-signal
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Argireline and Syn-Coll have published these mechanism-level observations. Not a co-administration recommendation.
A palmitoylated tripeptide marketed as a collagen-synthesis signal peptide with a thrombospondin-1 TGF-β-activation mimicry rationale. Stacks cleanly with Argireline for combined "neuromodulation + collagen-remodelling" formulation design.
SNAP-25 mimetic peptide that interferes with SNARE-complex assembly, reducing acetylcholine release at neuromuscular junctions and softening expression-line formation. Mechanistically entirely distinct from Syn-Coll (peripheral neurotransmitter inhibition vs dermal matrix signaling). Commonly layered in multi-peptide eye creams and expression-line serums — Syn-Coll addresses structural matrix, Argireline addresses muscle-driven line formation.
Quick facts
Argireline
Syn-Coll
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Argireline | Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. doi: 10.3390/ijms26125722. PMID: 40565185. (Most recent systematic review; formulation science is the domin… PMID 40565185 | systematic review |
| 2019 | Argireline | Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019 Jun;31(3):263-271. doi: 10.5021/ad.2019.31.3.263.… PMID 33911590 | human trial |
| 2017 | Argireline | Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017 Jun;16(2):271-278. doi: 10.1111/jocd.12314. PMID: 28150423. (Four-ar… PMID 28150423 | human trial |
| 2013 | Argireline | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi: 10.1007/s40257-013-0009-9. PMID: 23417317. (The largest ran… PMID 23417317 | human trial |
| 2013 | Argireline | Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013 Mar;20(3):515-518. doi: 10.1111/ene.12009. PMID: 23146065. (NIH / NIN… PMID 23146065 | human trial |
| 2002 | Argireline | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi: 10.1046/j.1467-2494.2002.00153.x. PMID: 184985… PMID 18498523 | human pilot |
| 2013 | Argireline | Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013 Aug;15(4):237-241. doi: 10.3109/14764172.2013.769273. PMID: 23607739. (Companion murine / clinical paper — D-galactose-aged… PMID 23607739 | preclinical, in vivo |
| 2015 | Argireline | Kraeling MEK, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi: 10.3109/15569527.2014.894521. PMID: 24754410. (Independent FDA in vitro penetration study — ~0.22% of 10% appl… PMID 24754410 | preclinical, in vitro |
| 2021 | Argireline | Lim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PCL, Kang L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J Control Release. 2021 Jan 10;329:907-918. doi: 10.1016/j.jconrel.2020.10.021. PMID… PMID 33068646 | pharmacology |
| 2020 | Argireline | Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 26;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195060. (Contextual review of cosmetic-peptide biochemistry and categorisation;… PMID 33195060 | review |
| 2024 | Argireline | Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. doi: 10.2196/54217. PMID: 38376906. (Google Trends analysis 2013-2023; post-2022 TikTok-driven consumer search surge; coining of "Botox in a bottle" in popular culture.) PMID 38376906 | research article |
| 2020 | Argireline | Lim SH, Tiew WJ, Zhang J, Ho PC, Kachouie NN, Kang L. Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptide. Biofabrication. 2020;12(3):035003. doi: 10.1088/1758-5090/ab6d37. PMID: 31952064. (3D-printed personalis… PMID 31952064 | research article |
| 1998 | Syn-Coll | Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159-1170. doi:10.1016/s0092-8674(00)81460-9. PMID: 9657149. (Genetic demonstration in TSP-1-null mice th… PMID 9657149 | preclinical, in vivo |
| 1987 | Syn-Coll | Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247(3):597-604. doi:10.1042/bj2470597. PMI… PMID 3501287 | preclinical, in vitro |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem. 2004;279(36):38032-38039. doi:10.1074/jbc.M405658200. PMID: 15208302. (Biochemical characterization of the LAP "latency lasso" that TSP-1 KRFK disrupts.) PMID 15208302 | mechanism / discovery |
| 1992 | Syn-Coll | Murphy-Ullrich JE, Schultz-Cherry S, Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell. 1992;3(2):181-188. doi:10.1091/mbc.3.2.181. (Original biochemical characterization of the TSP-1 / TGF-β complex.) | mechanism / discovery |
| 1986 | Syn-Coll | Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261(9):4337-4345. PMID: 3456347. (Early demonstration of TGF-β–driven matrix gene expression; co-… PMID 3456347 | mechanism / discovery |
| 2018 | Syn-Coll | Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biol. 2018;68-69:28-43. doi:10.1016/j.matbio.2017.12.009. (Comprehensive modern review of TSP-1 / TGF-β targeting for disease; PMC6015530.) | review |
| 2007 | Syn-Coll | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (The most widely cited dermatology review of cosmeceutical peptides; positions palmitoyl tripeptide-5 within the signal-peptide class.) PMID 18045359 | review |
| 2000 | Syn-Coll | Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1-2):59-69. doi:10.1016/s1359-6101(99)00029-5. PMID: 10708953. (Definitive mechanistic review of TSP-1-dependent TGF-β activation.) PMID 10708953 | review |
| — | Syn-Coll | Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides and Palmitoyl Polypeptides as Used in Cosmetics. Int J Toxicol. CIR Final Report (periodic updates). (Regulatory safety review of the palmitoyl-peptide class, including palmitoyl tripeptide-5.) | review |
| 2009 | Syn-Coll | Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416, v. doi:10.1016/j.det.2009.05.006. PMID: 19850190. (Dermatology practice-level overview of cosmeceutical peptide use, including TGF-β–mimetic tripeptides.) PMID 19850190 | research article |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem. 2004;279(46):47633-47642. doi:10.1074/jbc.M404918200. PMID: 15347654. (Identification of the WxxW "do… PMID 15347654 | research article |
| 1999 | Syn-Coll | Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem. 1999;274(19):13586-13593. doi:10.1074/… PMID 10224129 | research article |
Related pair pages
More research context
Frequently asked
Have Argireline and Syn-Coll been studied together?
Researchers have published mechanistic-level co-administration discussion of Argireline and Syn-Coll. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Argireline and Syn-Coll share?
Argireline and Syn-Coll share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Argireline and Syn-Coll?
Argireline: Cosmetic ingredient (not a drug). Syn-Coll: Cosmetic ingredient (not drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Argireline and Syn-Coll?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Argireline profile and the Syn-Coll profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026